Brain enzyme treatment relieves memory lapse in Alzheimer's mice

An enzyme that helps neurons rid themselves of excess or aberrant proteins is required for normal brain function, according to a new report in the August 25, 2006 issue of the journal Cell. What's more, by increasing brain levels of the enzyme in mice with Alzheimer's symptoms, the researchers found they could reverse lapses of memory characteristic of the debilitating disease.

Treatments that elevate the protein, known as ubiquitin C-terminal hydrolase L1 (Uch-L1), might therefore have potential as a new therapy for Alzheimer's disease, according to the researchers. Currently available therapies have almost exclusively targeted amyloid beta (Aß), the protein responsible for the "amyloid plaques" that riddle the brains of patients with Alzheimer's disease, they added.

"By injecting what is essentially a Uch-L1 drug to raise its levels in the brain, we were able to restore a great deal of brain activity in a transgenic mouse model of Alzheimer's disease," said Michael Shelanski of Columbia University.

"While amyloid beta is certainly a key player in Alzheimer's disease--and efforts to reduce it remain a worthy goal--our results show that, even in the presence of the plaque, damage to memory can be reversed."

The findings suggest that neurons' protein-ridding machinery, the so-called ubiquitin/proteasomal pathway, may play an important early role in the pathogenesis of Alzheimer's disease, he added.

Ubiquitin is a "tag" that marks proteins for destruction by the cellular "garbage disposal" known as the proteasome, Shelanski explained. Uch-L1 acts as the proteasome's "gatekeeper," he added. Before proteins can be eliminated by the proteasome, Uch-L1 must remove their ubiquitin tag.

Earlier studies found that the brains of Alzheimer's disease patients show an accumulation of ubiquitin-tagged proteins, suggesting some defect of the protein degradation machinery, the researchers noted. Studies of the brains of humans with Alzheimer's after death found evidence that the proteasome remained intact but largely unable to degrade proteins.

Interestingly, Uch-L1--a protein found almost exclusively in nerve cells--was also found at reduced levels in the Alzheimer's brain. Unpublished studies by Shelanski's group found that cells treated with Aß exhibited a rapid drop in Uch-L1, he said.

To further investigate in the current study, the researchers treated brain slices with a chemical that blocks Uch-L1 function. The treated brain tissue displayed a decline in "long-term potentiation" (LTP), a process whereby nerve connections are strengthened. LTP is regarded as the cellular basis for learning and memory.

Treatments that restored Uch-L1 levels corrected deficits in nerve transmission both in brain slices treated with Aß and in slices taken from transgenic mice with mutations that lead to elevated Aß and associated cognitive decline.

The researchers next asked whether Uch-L1 played an important role in fear conditioning, a form of learning known to be impaired in several mouse models of Alzheimer's disease.

For fear conditioning, mice treated with the Uch-L1 inhibitor and control mice were placed in a novel context (a fear-conditioning box) and exposed to a tone paired with a mild foot shock. Their ability to learn fear was tested 24 hr later by measuring "freezing" behavior in response to the box or the auditory cue. Contextual versus cued responses represent different forms of learning that depend on different parts of the brain.

A day after their exposure to the shock, mice with reduced levels of Uch-L1 showed a decrease in freezing behavior to 65% that of normal mice when placed in the box. The differences between treated and untreated mice persisted 7, 14, and 21 days after exposure to the electric shock, they reported.

On the other hand, the mice showed no differences in response to the auditory tone, suggesting variation among brain regions in the role of Uch-L1.

In mice with symptoms that mimic those found in patients with Alzheimer's disease, treatments that raised Uch-L1 greatly increased their freezing time compared to their transgenic littermates when contextual learning was assessed over time, the researchers found. Improvements in the treated animals' ability to establish a memory for fear did not depend on changes in Aß levels.

The findings provide a new window into the Alzheimer's brain that could lead to new therapies, the researchers said.

"The rapid fall in Uch-L1 activity in response to Aß raises the possibility that, in the Alzheimer's brain, Aß initiates a signaling cascade that results in the partial inhibition of proteasome activity more rapidly than is likely as the result of the accumulation of misfolded or undigestable proteins."

"Our data suggest that Uch-L1 could be an attractive target for the development of new therapeutic approaches to Alzheimer's disease, either alone or in combination with therapies that alter Aß levels."

Source: Cell Press

Related stories:

When a light goes on during thought processes
(PhysOrg.com) -- Thought processes made visible: An international team of scientists headed by Mazahir Hasan of the Max Planck Institute for Medical Research in Heidelberg has succeeded in optically detecting individual action potentials in the brains of living animals. The scientists introduced fluorescent indicator proteins into the brain cells of mice via viral gene vectors: the illumination of the fluorescent proteins indicates both when and which neurons are communicating with each other.
Protecting patient privacy the new fashioned way
Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act.
Study confirms benefit of combination therapy for Alzheimer's disease
Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ability to perform daily activities. Results from the first long-term study of the real-world use of Alzheimer's drugs, published by researchers from Massachusetts General Hospital in the July/September issue of Alzheimer Disease and Associated Disorders, support a level of effectiveness that may not be immediately apparent to patients or their family members.
A blood marker may indicate Alzheimer’s risk
A simple blood test capable of predicting if a person might develop Alzheimer’s disease is within sight, and could eventually be used to help scientists reverse onset of the disease in those most at risk.
Signs of Alzheimer's disease may be present decades before diagnosis
Scientists from the University of South Florida and the University of Kentucky report that people who develop Alzheimer's disease may show signs of this illness many decades earlier in life, including compromised educational achievement. Their research appears online this month in the journal Alzheimer's Disease and Associated Disorders.
New study finds healthy children of Alzheimer patients show early brain changes
Medical College of Wisconsin researchers in Milwaukee have reported that children of Alzheimer's patients who are carriers of a genetic risk factor for Alzheimer's disease have neurological changes that are detectable long before clinical symptoms may appear.
New Membrane Model May Unlock Secrets of Early-Stage Alzheimer's
Researchers at the National Institute of Standards and Technology and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer’s disease actually impairs a neuron’s structure and function. The team’s findings are reported in a new paper in the Biophysical Journal.
Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain
Neuroscientists at Cold Spring Harbor Laboratory (CSHL) are part of a collaboration that has succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.

News discussion:

Medicine & Health news